Enteropathy-associated T-cell lymphoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}} {{AS}} | ||
==Overview== | ==Overview== | ||
Common complications of enteropathy-associated T-cell lymphoma include ulcer, obstruction, and perforation of small intestine.<ref name= canadiancancer>Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016 </ref> | |||
==Complications== | |||
* Common complications of enteropathy-associated T-cell lymphoma include:<ref name= canadiancancer>Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016 </ref> | |||
:* Ulcer in small intestine | |||
:* Obstruction of small intestine | |||
:* Perforation of small intestine | |||
==Prognosis== | ==Prognosis== | ||
* EATL is usually a fast-growing (aggressive) lymphoma. The prognosis for people with EATL is often not very good.<ref name= canadiancancer>Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016 </ref> | |||
* Recurrences most frequent in the small intestine<ref name=cancer.gov> Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016</ref> | * Recurrences most frequent in the small intestine<ref name=cancer.gov> Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016</ref> | ||
* According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months | * According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months | ||
Revision as of 18:52, 27 January 2016
|
Enteropathy-associated T-cell lymphoma Microchapters |
|
Differentiating Enteropathy-associated T-cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
FDA on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
CDC on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis in the news |
|
Blogs on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Common complications of enteropathy-associated T-cell lymphoma include ulcer, obstruction, and perforation of small intestine.[1]
Complications
- Common complications of enteropathy-associated T-cell lymphoma include:[1]
- Ulcer in small intestine
- Obstruction of small intestine
- Perforation of small intestine
Prognosis
- EATL is usually a fast-growing (aggressive) lymphoma. The prognosis for people with EATL is often not very good.[1]
- Recurrences most frequent in the small intestine[2]
- According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months
- The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma
- Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm[3]
- Autologous stem cell transplantation is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients
- One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)[4]
References
- ↑ 1.0 1.1 1.2 Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016
- ↑ Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016
- ↑ Delabie J, et al. (July 2011). "Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project". Blood. 118 (148): 148. doi:10.1182/blood-2011-02-335216.
- ↑ Jantunen, E; Boumendil, A; Finel, H; Luan, J. J.; Johnson, P; Rambaldi, A; Haynes, A; Duchosal, M. A.; Bethge, W; Biron, P; Carlson, K; Craddock, C; Rudin, C; Finke, J; Salles, G; Kroschinsky, F; Sureda, A; Dreger, P; Lymphoma Working Party of the EBMT (2013). "Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT". Blood. 121 (13): 2529–32. doi:10.1182/blood-2012-11-466839. PMID 23361910.